Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suizenji in Unresectable Pancreatic Cancer
NCT05601323Active, not recruiting
- Sponsor
- SONIRE Therapeutics
- Start
- Jan 2023
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Randomised trial in pancreatic cancer (PC) (2 arms), sponsored by SONIRE Therapeutics. Primary endpoint: Overall Survival at 24 months. Started Jan 2023; status: active, not recruiting.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05601323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601323.